Mark Fineman

SchoolVc-academic Affairs
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study. Rheumatol Ther. 2023 Dec; 10(6):1741-1752. Fineman MS, McAlindon TE, Lattermann C, Swearingen CJ, Kennedy S, Lopez VA, Simsek I, Tambiah JRS, Yazici Y. PMID: 37902943; PMCID: PMC10654271.
      View in: PubMed   Mentions:
    2. First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations. Diabetes Obes Metab. 2023 09; 25(9):2447-2456. Fineman MS, Bryant CLN, Colbert K, Jozefiak TH, Petersen JS, Horowitz M, Vora J, Rayner CK, Wabnitz P, Nimgaonkar A. PMID: 37380614.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLoS One. 2018; 13(9):e0203946. Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, Bicsak TA, Baron A, Fineman M. PMID: 30252913; PMCID: PMC6155522.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    4. Metformin-associated lactic acidosis: Moving towards a new paradigm? Diabetes Obes Metab. 2017 11; 19(11):1499-1501. Bicsak TA, Walsh B, Fineman M. PMID: 28474371; PMCID: PMC5655765.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    5. Spinal Disinhibition in Experimental and Clinical Painful Diabetic Neuropathy. Diabetes. 2017 05; 66(5):1380-1390. Marshall AG, Lee-Kubli C, Azmi S, Zhang M, Ferdousi M, Mixcoatl-Zecuatl T, Petropoulos IN, Ponirakis G, Fineman MS, Fadavi H, Frizzi K, Tavakoli M, Jeziorska M, Jolivalt CG, Boulton AJM, Efron N, Calcutt NA, Malik RA. PMID: 28202580; PMCID: PMC5399611.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimals
    6. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016 08; 59(8):1645-54. DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, Fineman M. PMID: 27216492; PMCID: PMC4930485.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    7. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016 Feb; 39(2):198-205. Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. PMID: 26285584.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansCTClinical Trials
    8. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013 Jan 12; 381(9861):117-24. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G. PMID: 23141817.
      View in: PubMed   Mentions: 188     Fields:    Translation:Humans
    9. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun; 14(6):546-54. Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. PMID: 22236356.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    10. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011 Jan; 50(1):65-74. Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, Walsh B, Diamant M, Cirincione B, Kothare P, Li WI, MacConell L. PMID: 21142268.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    11. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clin Ther. 2009 Apr; 31(4):806-15. Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. PMID: 19446153.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    12. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol. 2008 Dec; 48(12):1389-99. Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, de la Peña A, Teng CH, Mace K, Fineman M, Shigeta H, Sakata Y, Irie S. PMID: 19047364.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    13. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008 Nov 29; 151(1-3):123-9. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M. PMID: 18675854.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    14. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007 Aug; 9(4):317-26. Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. PMID: 17705687.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    15. Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes. J Clin Pharmacol. 2007 Jul; 47(7):798-805. Kellmeyer TA, Kesty NC, Wang Y, Frias JP, Fineman MS. PMID: 17463219.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007 Jun; 30(6):1487-93. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K. PMID: 17353504.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    17. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005 Nov; 90(11):5991-7. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA. PMID: 16144950.
      View in: PubMed   Mentions: 99     Fields:    Translation:Humans
    18. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther. 2005 Jun; 7(3):467-77. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D. PMID: 15929678.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    19. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol. 2005 May; 45(5):570-7. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. PMID: 15831781.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    20. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005 May; 28(5):1083-91. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. PMID: 15855571.
      View in: PubMed   Mentions: 304     Fields:    Translation:HumansCTClinical Trials
    21. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 May; 28(5):1092-100. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. PMID: 15855572.
      View in: PubMed   Mentions: 392     Fields:    Translation:HumansCTClinical Trials
    22. Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm. 2005 Apr 15; 62(8):816-22. Weyer C, Fineman MS, Strobel S, Shen L, Data J, Kolterman OG, Sylvestri MF. PMID: 15821274.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    23. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005 Feb; 27(2):210-5. Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M. PMID: 15811484.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    24. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005 Jan 15; 62(2):173-81. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. PMID: 15700891.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCTClinical Trials
    25. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 Nov; 27(11):2628-35. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group. PMID: 15504997.
      View in: PubMed   Mentions: 323     Fields:    Translation:HumansCTClinical Trials
    26. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004 Sep; 53(9):2397-403. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O. PMID: 15331551.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    27. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004 Sep-Oct; 20(5):411-7. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. PMID: 15343588.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    28. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004 Apr; 12(4):661-8. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C. PMID: 15090634.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    29. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev. 2004 Jan-Feb; 20(1):55-60. Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C. PMID: 14737746.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    30. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003 Aug; 26(8):2370-7. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. PMID: 12882864.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    31. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003 Jul; 88(7):3082-9. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. PMID: 12843147.
      View in: PubMed   Mentions: 140     Fields:    Translation:HumansCTClinical Trials
    32. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003 Mar; 26(3):784-90. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. PMID: 12610038.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    33. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002 Apr; 25(4):724-30. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. PMID: 11919132.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    34. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002; 4(1):51-61. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. PMID: 12017421.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    Mark's Networks
    Concepts (113)
    Derived automatically from this person's publications.
    Co-Authors (5)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department